US 12,152,081 B2
Chimeric antigen receptors targeting CD70
Surabhi Srivatsa Srinivasan, San Francisco, CA (US); Niranjana Nagarajan, Oakland, CA (US); Siler Panowski, Berkeley, CA (US); Yoon Park, Seoul (KR); Tao Sai, Foster City, CA (US); Barbra Sasu, San Francisco, CA (US); Thomas Van Blarcom, Oakland, CA (US); Mathilde Dusseaux, Creteil (FR); and Roman Galetto, Paris (FR)
Assigned to Pfizer Inc., New York, NY (US)
Filed by Pfizer Inc., New York, NY (US)
Filed on Jun. 17, 2022, as Appl. No. 17/843,616.
Application 17/843,616 is a division of application No. 16/264,371, filed on Jan. 31, 2019, granted, now 11,396,551.
Claims priority of provisional application 62/775,246, filed on Dec. 4, 2018.
Claims priority of provisional application 62/641,873, filed on Mar. 12, 2018.
Claims priority of provisional application 62/641,869, filed on Mar. 12, 2018.
Claims priority of provisional application 62/625,019, filed on Feb. 1, 2018.
Claims priority of provisional application 62/625,009, filed on Feb. 1, 2018.
Prior Publication US 2023/0041456 A1, Feb. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/02 (2006.01); A61P 35/04 (2006.01); C07K 14/725 (2006.01)
CPC C07K 16/2875 (2013.01) [A61K 39/001129 (2018.08); A61K 39/001138 (2018.08); A61P 35/02 (2018.01); A61P 35/04 (2018.01); C07K 14/7051 (2013.01); A61K 2039/5156 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01)] 42 Claims
 
1. A method of treating a CD70-associated disease in a subject, comprising administering to the subject an immune cell expressing at its surface a chimeric antigen receptor (CAR), wherein the CAR comprises an extracellular ligand-binding domain that specifically binds to CD70, a first transmembrane domain, and an intracellular signaling domain, wherein the extracellular ligand-binding domain comprises a variable heavy chain (VH) domain comprising amino acid sequences for CDRH1, CDRH2, and CDRH3 and a variable light chain (VL) domain comprising amino acid sequences for CDRL1, CDRL2, and CDRL3, wherein:
the CDRH1 comprises an amino acid sequence selected from SEQ ID NOs: 97-99,
the CDRH2 comprises an amino acid sequence selected from SEQ ID NOs: 100-101,
the CDRH3 comprises the amino acid sequence of SEQ ID NO: 102,
the CDRL1 comprises the amino acid sequence of SEQ ID NO: 217,
the CDRL2 comprises the amino acid sequence of SEQ ID NO: 218, and
the CDRL3 comprises the amino acid sequence of SEQ ID NO: 219.